Source: PHARMACEUTICAL BUSINESS REVIEW

Revalesio: Revalesio's RNS60 shows promise in treating Alzheimer's disease and other dementias

Revalesio and Rush University Medical Center's Department of Neurological Sciences published findings from two research studies that demonstrate the potential for RNS60 to treat Alzheimer's disease and other forms of dementia by protecting neuronal function, restoring neuronal connections and promoting neuronal plasticity.

Read full article »
Est. Annual Revenue
$100K-5.0M
Est. Employees
25-100
Eric Russell's photo - Chairman & CEO of Revalesio

Chairman & CEO

Eric Russell

CEO Approval Rating

68/100

Read more